UPDATE: Baird Upgrades Arrowhead Research (ARWR) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
SVB Leerink Downgrades The Medicines Company (MDCO) to Market Perform
November 25, 2019 8:10 PM ESTSVB Leerink analyst Joseph Schwartz downgraded The Medicines Company (NASDAQ: MDCO) from Outperform to Market Perform with a price target of $85.00 (from $78.00).
For an analyst ratings summary and ratings history on The Medicines Company... More
